Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review

Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review

Blog Article

Ahmed Mohammed Albakri, Ahmed Paper Hussein Subki, Abdurahman Albeity, Hussein Halabi Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaCorrespondence: Ahmed Hussein Subki; Hussein Halabi, Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, POBox: 43129, Jeddah, 21561, Saudi Arabia, Tel +966566724288, Email [email protected]; [email protected]: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been a sudden surge in the incidence of several immune-mediated diseases, including dermatomyositis.The reported cases of COVID-19-related dermatomyositis are heterogeneous in their clinical presentation and implemented therapies.

Case Study: We report a 23-year-old female patient diagnosed with a 3-year history of dermatomyositis.She has been well-controlled on maintenance therapy.However, 6 weeks after a mild COVID-19 infection, she developed a dermatomyositis flare.She improved only after aggressive treatment with pulse steroids, intravenous immunoglobulin, and rituximab.Conclusion: Exacerbation of dermatomyositis can be encountered following a COVID-19 Incline Motor infection, even if the infection is mild.

Aggressive therapy should be considered in such cases.The prognosis, however, is generally favorable.Keywords: COVID-19 infection, dermatomyositis, Rituximab.